Drug Trial Radar · NCT07446257
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Sep 1, 2029
Study completion Sep 1, 2030
Sponsor
- Lead sponsor
- University of Texas Southwestern Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Maia Biotechnology; National Cancer Institute (NCI)
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).
Conditions
- Resectable Hepatocellular Carcinoma
Interventions
ateganosineDrug
ateganosine: 180 mg IV D1, D2, D3 of 21-day cycle
CadonilimabDrug
cadonilimab: 10 mg/kg IV D5 of 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-related delay of surgical resection >28 days from expected surgery date.Time frame: 28 days after the expected surgery date (day 5 of cycle 3 for all treatment arms)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.